Inflammatory bowel disease in pregnancy: management strategy based on best evidence and European guidelines

Kubota-Sjogren, Yukiko; Harding, Kate; Irving, Peter M; Nelson‐Piercy, Catherine

doi:10.3399/bjgp14x682513

Cited by 5 publications

(4 citation statements)

References 4 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recommendations regarding the timing of the last dose of biologics concerning delivery, restarting biologics in the postpartum period, and any required alterations in the neonatal vaccination schedule are addressed in the updated European Crohn’s and colitis organization (ECCO) guidelines. [ 84 ]…”

Section: Patient and Disease Characteristicsmentioning

confidence: 99%

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Mukhtar,

Mosli

2024

Saudi Journal of Gastroenterology

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic autoimmune inflammatory disease that affects the colon, leading to symptoms of bloody diarrhea, abdominal cramps, and urgency. The treatment of UC has evolved over the past few decades from locally active anti-inflammatory compounds to more selective therapies that target specific arrays of the immune system. The challenge of selecting the first advanced therapy became apparent in this rapidly expanding landscape of medications. No current investigational tools, such as genetic, immunologic, or biological markers, can guide the identification of the safest and most effective therapeutic option for each patient. Hence, physicians must carefully assess patient/disease characteristics and match them with the most suitable drug through a clinically driven assessment. In this paper, we outline patient and drug characteristics that play a role in selecting first-line advanced therapies for UC and propose an algorithm for selection.

show abstract

Section: Patient and Disease Characteristicsmentioning

confidence: 99%

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Mukhtar,

Mosli

2024

Saudi Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…This inhibition leads to a folate deficiency in patients that consequently increases the chances of developing colorectal cancer and megaloblastic anemia, as well as defects, in newborns [ 3 , 4 , 5 , 6 ]. To maintain a sufficient folate concentration in IBD patients, a supplementation of folic acid (FA) during the regular therapy of IBD is mandatory, usually in elevated doses of 1–5 mg/day compared to the intake of 0.4 mg/day in healthy people [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Drug–Drug Compatibility Evaluation of Sulfasalazine and Folic Acid for Fixed-Dose Combination Development Using Various Analytical Tools

et al. 2021

View full text Add to dashboard Cite

The simultaneous administration of sulfasalazine and folic acid is regular practice in the therapy of inflammatory bowel diseases in order to maintain sufficient folate concentration in patients. Having multiple drugs in the therapy increases the possibility of patients failing adherence, thus unintentionally endangering their health. A fixed-dose combination of sulfasalazine and folic would simplify the classical polytherapeutic approach; however, the physicochemical compatibility investigation of two active pharmaceutical ingredients plays an important role in the development of such a product. In this work, various analytical tools were used to determine the physicochemical compatibility of sulfasalazine and folic acid. For the evaluation of chemical compatibility, infrared spectroscopy in combination with advanced statistical methods, such as the principal component analysis and cluster analysis, were used, whilst a simultaneous thermogravimetry/differential thermal analysis gave us an insight into the physical compatibility of two drugs. Isothermal stress testing, forced degradation and dissolution studies, followed by the analysis with a developed chromatographic method for the monitoring of folic acid, sulfasalazine and two of its related impurities, sulfapyridine and salicylic acid, gave us an insight into its chemical compatibility. The combination of the results obtained from the used techniques implies a satisfactory physicochemical compatibility between sulfasalazine and folic acid, which opens the path to the development of the proposed fixed-dose combination.

show abstract

“…[9][10][11] FA deficiency is easily controlled and supplemented by taking a FA oral dosage form during regular therapy of IBD, however, elevated doses of 1-5 mg per day are mandatory compared to the regular intake of 0.4 mg per day. [12] As simple as it sounds that taking only one additional pill during therapy can solve the problem of malabsorbed FA, therapy nonadherence is one of the biggest threats to effective treatment of not only IBD, but also a variety of diseases that are based on polytherapy. [13][14][15] One of the ways this problem was approached was the development of so-called fixed-dose combinations (FDCs).…”

Section: Introductionmentioning

confidence: 99%

Thermoanalytical, Spectroscopic and Chromatographic Approach to Physicochemical Compatibility Investigation of 5-Aminosalicylates and Folic Acid

Jeličić¹,

Brusač²,

Kurajica³

et al. 2021

Croat. Chem. Acta

View full text Add to dashboard Cite

Inflammatory bowel disease in pregnancy: management strategy based on best evidence and European guidelines

Cited by 5 publications

References 4 publications

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Drug–Drug Compatibility Evaluation of Sulfasalazine and Folic Acid for Fixed-Dose Combination Development Using Various Analytical Tools

Thermoanalytical, Spectroscopic and Chromatographic Approach to Physicochemical Compatibility Investigation of 5-Aminosalicylates and Folic Acid

Contact Info

Product

Resources

About